AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34564955 — intervention group
Group type: EXPERIMENTAL
Intervention: High mutations in fatty acid metabolism pathway (mut-high)
Number of subjects: 52
Study 34565452 — intervention group
Group type: EXPERIMENTAL
Intervention: Histone H3 acetylation on lysine 27 (H3K27ac) in 18-week-old children
Number of subjects: 36
Study 34565452 — intervention group
Group type: EXPERIMENTAL
Intervention: Histone H3 acetylation on lysine 27 (H3K27ac) in 1-year-old children
Number of subjects: 36
Study 34565452 — intervention group
Group type: EXPERIMENTAL
Intervention: One-carbon metabolism analysis in 1-year-old children
Number of subjects: 36
Study 34566628 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS) with an average pulse amplitude of 6.25 mA and stimulation period of 440.7 seconds
Number of subjects: 20
Study 34566706 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive Functions and Parental Anxiety
Number of subjects: 0
Study 34566708 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Number of subjects: 0
Study 34566840 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS)-based cerebral autoregulation index
Number of subjects: 0
Study 34566840 — intervention group
Group type: EXPERIMENTAL
Intervention: Index of focal cerebral oxygenation
Number of subjects: 0
Study 34566853 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Supported Discharge
Number of subjects: 0
Study 34566853 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 34567118 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 918
Study 34567118 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy
Number of subjects: 918
Study 34567118 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor size
Number of subjects: 918
Study 34567926 — intervention group
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Number of subjects: 11051
Study 34568006 — intervention group
Group type: EXPERIMENTAL
Intervention: 2173 CAR T cells
Number of subjects: 0
Study 34568057 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted thoracoscopic surgery (RATS)
Number of subjects: 83
Study 34568057 — intervention group
Group type: COMPARATOR
Intervention: Video-assisted thoracic surgery (VATS)
Number of subjects: 83
Study 34568058 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib and Osimertinib
Number of subjects: 10
Study 34568066 — intervention group
Group type: EXPERIMENTAL
Intervention: Treosulfan-based conditioning regimen (42 g/m²)
Number of subjects: 0
Study 34568241 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Slow Expiration Technique
Number of subjects: 0
Study 34568241 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 34568375 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate
Number of subjects: 0
Study 34568375 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 34568387 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 0
Study 34568387 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol
Number of subjects: 0
Study 34568719 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated 31-GEP neural network algorithm incorporating clinicopathologic features with the continuous 31-GEP score.
Number of subjects: 3372
Study 34568984 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-CTCAE severity item
Number of subjects: 142
Study 34568984 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-CTCAE interference item
Number of subjects: 142
Study 34568984 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-CTCAE severity and interference items
Number of subjects: 142
Study 34568984 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-CTCAE severity and interference response categories
Number of subjects: 142
Study 34568984 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-CTCAE items
Number of subjects: 142
Study 34569250 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque erosion treatment with stenting
Number of subjects: 579
Study 34569250 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group comparison
Number of subjects: 579
Study 34569278 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery Protocol
Number of subjects: 0
Study 34569278 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care (Control)
Number of subjects: 0
Study 34569467 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat-based telemedicine intervention
Number of subjects: 1424
Study 34569467 — intervention group
Group type: COMPARATOR
Intervention: Conventional community hospital follow-up
Number of subjects: 1424
Study 34569839 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34569847 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based pediatric weight management intervention (PWMI); details on dosage and duration not available.
Number of subjects: 0
Study 34569848 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric weight management intervention, details not available
Number of subjects: 0
Study 34569848 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 34570085 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey on attitudes and perceptions regarding pharmacogenomics
Number of subjects: 149
Study 34570185 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthyroid state
Number of subjects: 18
Study 34570185 — intervention group
Group type: COMPARATOR
Intervention: Euthyroid state
Number of subjects: 18
Study 34570185 — intervention group
Group type: COMPARATOR
Intervention: 3 months after normal thyroid function
Number of subjects: 18
Study 34570342 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine deficiency
Number of subjects: 726
Study 34570352 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass (CPB)
Number of subjects: 35
Study 34570352 — intervention group
Group type: COMPARATOR
Intervention: No cardiopulmonary bypass (CPB)
Number of subjects: 35
Study 34570534 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (not specified dosage or duration)
Number of subjects: 0
Study 34570645 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 10
Study 34570655 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R regimen (dose-adjusted etoposide, doxorubicin, cyclophosphamide with vincristine and prednisone plus rituximab)
Number of subjects: 46
Study 34570655 — intervention group
Group type: COMPARATOR
Intervention: Historical control (not specified in detail)
Number of subjects: 46
Study 34570677 — intervention group
Group type: EXPERIMENTAL
Intervention: System Support Mapping (MAP)
Number of subjects: 24
Study 34570768 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary endothelial-dependent variables (change in coronary blood flow and coronary diameter in response to cold pressor testing)
Number of subjects: 152
Study 34570811 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized history-taking (CHT)
Number of subjects: 0
Study 34570811 — intervention group
Group type: COMPARATOR
Intervention: Electronic health records (EHR)
Number of subjects: 0
Study 34570984 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow weight loss program
Number of subjects: 30
Study 34570984 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast weight loss program
Number of subjects: 30
Study 34571258 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathy (osteoporosis or osteopenia) identified via DXA scan
Number of subjects: 282
Study 34571258 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic fractures
Number of subjects: 282
Study 34571258 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous fractures
Number of subjects: 282
Study 34571258 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 282
Study 34571258 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 282
Study 34571258 — intervention group
Group type: EXPERIMENTAL
Intervention: White race
Number of subjects: 282
Study 34571258 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight body mass index category
Number of subjects: 282
Study 34571503 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable, self-contained neuroprosthetic hand with deep learning-based finger control
Number of subjects: 0
Study 34572728 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-Learning automatic segmentation algorithm (DLASA) for measuring muscle depletion (MD)
Number of subjects: 656
Study 34572728 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-Learning automatic segmentation algorithm (DLASA)
Number of subjects: 656
Study 34572852 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy followed by potentially curative gastric cancer resection
Number of subjects: 606
Study 34572852 — intervention group
Group type: EXPERIMENTAL
Intervention: Other events (concurrent distant metastasis, locoregional recurrence or death)
Number of subjects: 606
Study 34573883 — intervention group
Group type: EXPERIMENTAL
Intervention: OCTA measurements in DM-no DR patients with HbA1c levels >7.5%
Number of subjects: 478
Study 34574679 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry juice
Number of subjects: 45
Study 34574679 — intervention group
Group type: EXPERIMENTAL
Intervention: Blueberry juice
Number of subjects: 45
Study 34574679 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cherry/blueberry flavoured)
Number of subjects: 45
Study 34575192 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 0
Study 34575252 — intervention group
Group type: EXPERIMENTAL
Intervention: P-HNL Dimer
Number of subjects: 103
Study 34575252 — intervention group
Group type: EXPERIMENTAL
Intervention: B-HNL
Number of subjects: 103
Study 34576834 — intervention group
Group type: EXPERIMENTAL
Intervention: 2'fucosyllactose (2'FL) and lacto-N-neotetraose (LNnT) formula feeding
Number of subjects: 0
Study 34576834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34579117 — intervention group
Group type: EXPERIMENTAL
Intervention: Full Healthy Primary School of the Future (HPSF)
Number of subjects: 833
Study 34579117 — intervention group
Group type: COMPARATOR
Intervention: Partial Healthy Primary School of the Future (HPSF)
Number of subjects: 833
Study 34579646 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma transfusion (CP); median infusion titers 1:320 U/mL (Interquartile range 1:80-1:320)
Number of subjects: 50
Study 34579718 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe multimorbidity (591; 6.5%)
Number of subjects: 9566
Study 34579718 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate multimorbidity (4301; 47.6%)
Number of subjects: 9566
Study 34579718 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild multimorbidity (4147; 45.9%)
Number of subjects: 9566
Study 34579718 — intervention group
Group type: COMPARATOR
Intervention: Severe multimorbidity compared to mild
Number of subjects: 9566
Study 34579718 — intervention group
Group type: COMPARATOR
Intervention: Moderate multimorbidity compared to mild
Number of subjects: 9566
Study 34579718 — intervention group
Group type: COMPARATOR
Intervention: Severe class compared to mild class
Number of subjects: 9566
Study 34579767 — intervention group
Group type: EXPERIMENTAL
Intervention: WJ-MSC and rEMS combination (Group 1)
Number of subjects: 18
Study 34579767 — intervention group
Group type: COMPARATOR
Intervention: Only rEMS (Group 2)
Number of subjects: 18
Study 34579767 — intervention group
Group type: EXPERIMENTAL
Intervention: Only WJ-MSC (Group 3)
Number of subjects: 18
Study 34579768 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified natural cycle FET (corpus luteum present)
Number of subjects: 788
Study 34579768 — intervention group
Group type: COMPARATOR
Intervention: Programmed FET (corpus luteum absent)
Number of subjects: 788
Study 34579775 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (target dose 97/103 mg b.i.d.)
Number of subjects: 0
Study 34579775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34579786 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate bivalent HPV vaccine and delayed meningococcal vaccine (group 1)
Number of subjects: 0
Study 34579786 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate nonavalent HPV vaccine and delayed meningococcal vaccine (group 2)
Number of subjects: 0
Study 34579786 — intervention group
Group type: COMPARATOR
Intervention: Immediate meningococcal vaccine and delayed HPV vaccine (group 3)
Number of subjects: 0
Study 34580030 — intervention group
Group type: EXPERIMENTAL
Intervention: Transactional sex
Number of subjects: 454
Study 34580030 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgender identity
Number of subjects: 454
Study 34580030 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent unstable housing
Number of subjects: 454
Study 34580030 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived financial well-being
Number of subjects: 454
Study 34580030 — intervention group
Group type: EXPERIMENTAL
Intervention: Coerced sex
Number of subjects: 454
Study 34580030 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana use
Number of subjects: 454
Study 34580030 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable housing and sexual coercion
Number of subjects: 454
Study 34580115 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV sequencing (HPV-seq)
Number of subjects: 0
Study 34580115 — intervention group
Group type: COMPARATOR
Intervention: dPCR
Number of subjects: 0
Study 34580336 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab and Paclitaxel combination therapy
Number of subjects: 14
Study 34580404 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS-R (right-sided shoulder TENS)
Number of subjects: 0
Study 34580404 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS-L (left-sided shoulder TENS)
Number of subjects: 0
Study 34580404 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS (control group)
Number of subjects: 0
Study 34580668 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-positive patients with cancer
Number of subjects: 357
Study 34580668 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hematological malignancies
Number of subjects: 357
Study 34580673 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 µg NDV-HXP-S vaccine
Number of subjects: 210
Study 34580673 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 µg NDV-HXP-S vaccine
Number of subjects: 210
Study 34580673 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 µg NDV-HXP-S vaccine
Number of subjects: 210
Study 34580673 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 µg+CpG1018 NDV-HXP-S vaccine
Number of subjects: 210
Study 34580673 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 µg+CpG1018 NDV-HXP-S vaccine
Number of subjects: 210
Study 34580673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 34581443 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 0
Study 34581443 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34581517 — intervention group
Group type: EXPERIMENTAL
Intervention: SBI-101 (ex vivo mesenchymal stem cells)
Number of subjects: 0
Study 34581550 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal cardiovascular health for three or more of the seven health metrics
Number of subjects: 474
Study 34581550 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal cardiovascular health for two or fewer of the seven health metrics
Number of subjects: 474
Study 34581550 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor cardiovascular health for three or more of the seven health metrics
Number of subjects: 474
Study 34581550 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor cardiovascular health for two or fewer of the seven health metrics
Number of subjects: 474
Study 34581712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive functioning (3MS)
Number of subjects: 298
Study 34581712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive functioning (3MS) with METER
Number of subjects: 298
Study 34581712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive functioning (3MS) with REALM
Number of subjects: 298
Study 34581712 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy (METER)
Number of subjects: 298
Study 34581712 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy (REALM)
Number of subjects: 298
Study 34581757 — intervention group
Group type: EXPERIMENTAL
Intervention: RO6870810 + venetoclax
Number of subjects: 39
Study 34581757 — intervention group
Group type: EXPERIMENTAL
Intervention: RO6870810 + venetoclax + rituximab
Number of subjects: 39
Study 34581764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 5 mg twice daily (DL1)
Number of subjects: 18
Study 34581764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 10 mg twice daily (DL2)
Number of subjects: 18
Study 34581764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (both DLs)
Number of subjects: 18
Study 34581770 — intervention group
Group type: EXPERIMENTAL
Intervention: 44-channel suprachoroidal retinal prosthesis
Number of subjects: 4
Study 34581778 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 10
Study 34581993 — intervention group
Group type: EXPERIMENTAL
Intervention: LLD concurrent with adolescent idiopathic scoliosis (AIS)
Number of subjects: 47
Study 34581993 — intervention group
Group type: COMPARATOR
Intervention: LLD without concurrent AIS
Number of subjects: 47
Study 34582035 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA)
Number of subjects: 1042
Study 34582035 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K Antagonist (VKA)
Number of subjects: 1042
Study 34582035 — intervention group
Group type: COMPARATOR
Intervention: Direct Oral Anticoagulants (DOAC)
Number of subjects: 1042
Study 34582080 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized guidewires, microcatheters, and guide catheter extensions for CTO revascularization
Number of subjects: 150
Study 34582307 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 1 (BMI, stress level, diastolic blood pressure, narcotic use in 1st trimester, uterine artery pulsatility index at 16-21 weeks)
Number of subjects: 865
Study 34582307 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 2 (Model 1 variables plus preterm delivery, preeclampsia, and suspected fetal growth restriction)
Number of subjects: 865
Study 34582307 — intervention group
Group type: COMPARATOR
Intervention: Composite perinatal morbidity
Number of subjects: 865
Study 34582355 — intervention group
Group type: EXPERIMENTAL
Intervention: STAC-T web app prototype
Number of subjects: 16
Study 34582354 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAMPS Study and Registry
Number of subjects: 2762
Study 34582354 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up questionnaires
Number of subjects: 2762
Study 34582354 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal cohort
Number of subjects: 2762
Study 34582377 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime-boost vaccination regimen
Number of subjects: 0
Study 34582377 — intervention group
Group type: COMPARATOR
Intervention: Prime-only vaccination regimen
Number of subjects: 0
Study 34582562 — intervention group
Group type: COMPARATOR
Intervention: Antioxidants (silymarin)
Number of subjects: 345
Study 34582562 — intervention group
Group type: COMPARATOR
Intervention: Antipsychotics (olanzapine)
Number of subjects: 345
Study 34582562 — intervention group
Group type: COMPARATOR
Intervention: Cell signal transducers (inositol)
Number of subjects: 345
Study 34582562 — intervention group
Group type: COMPARATOR
Intervention: Glutamate modulators (N-acetylcysteine)
Number of subjects: 345
Study 34582562 — intervention group
Group type: COMPARATOR
Intervention: Opioid antagonists (naltrexone)
Number of subjects: 345
Study 34582562 — intervention group
Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs; fluoxetine)
Number of subjects: 345
Study 34582562 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic antidepressants (clomipramine)
Number of subjects: 345
Study 34582633 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing Time (ST)
Number of subjects: 72
Study 34582633 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary Behavior (SB)
Number of subjects: 72
Study 34582724 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cooling
Number of subjects: 0
Study 34582724 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 34583638 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy referral
Number of subjects: 711
Study 34583638 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-procedure visit completion
Number of subjects: 711
Study 34583638 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy completion
Number of subjects: 711
Study 34583638 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to colonoscopy
Number of subjects: 711
Study 34583690 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC-19QoL instrument
Number of subjects: 15
Study 34583690 — intervention group
Group type: COMPARATOR
Intervention: Control group of unaffected participants
Number of subjects: 15
Study 34583746 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-coated balloon angioplasty
Number of subjects: 478
Study 34583746 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-coated balloon angioplasty
Number of subjects: 478
Study 34583762 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (1-ml triamcinolone 40 mg/1 ml)
Number of subjects: 100
Study 34583762 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection co-administered with 1-ml of 1% lidocaine
Number of subjects: 100
Study 34584462 — intervention group
Group type: EXPERIMENTAL
Intervention: TVUS guided ET
Number of subjects: 800
Study 34584462 — intervention group
Group type: COMPARATOR
Intervention: TAUS guided ET
Number of subjects: 800
Study 34584574 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile mindful eating intervention
Number of subjects: 0
Study 34585083 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 1567